Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2021

View Archived Issues

NeuBase reports on three programs with PATrOL-enabled genetic medicines

New GLP-1 receptor agonists identified at ILDONG Pharmaceutical

Yuhan Corp. describes compositions including GDF15 variants

Bayer patents prostaglandin E2 receptor EP3 subtype antagonists

New tucaresol prodrugs discovered at Beyondspring Pharmaceuticals

Gilead discovers Mcl-1 inhibitors

Peptide-drug conjugate PEN-221 demonstrates efficacy in patients with GI neuroendocrine tumors

Lilly's SERD LY-3484356 well tolerated in first-in-human study

Urinary CCL5 mRNA is predictive of diabetic nephropathy progression

Shoreline and BeiGene collaborate to develop and commercialize NK-based cell therapies

ReNeuron provides update for hRPC therapy candidate study

ONK Therapeutics and Trinity College Dublin collaborate in an Enterprise Ireland funded project

First patient dosed in phase I study of BTX-A51 in advanced solid tumors

Two-year follow-up data from phase I/IIa study of LiPax in non-muscle invasive bladder cancer

TAS-3681 shows safety and antitumor activity against heavily pretreated, multidrug-resistant mCRPC

Atossa presents final data from phase II endoxifen breast cancer study

First European CTA accepted for phase I/II study of INZ-701 in ABCC6 deficiency

InCarda announces progress in development program for InRhythm

Preliminary phase I results reported for OMS-906

Phase I trial evaluates M-4076 in advanced solid tumors

GigaGen initiates first-in-human study of GIGA-2050 in COVID-19

Urinary DKK3 is a biomarker of CKD progression and mortality

At ASCO, radiopharmaceuticals score with lutetium-PSMA

Oxurion receives IRB approval for phase II study of THR-687 in DME

IMDC recommends continuation of phase IIb study of nangibotide in septic shock

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...